Hexagon Bio is a data-driven biopharma company developing targeted small molecule therapeutics. Our proprietary platform combines data science, genomics, synthetic biology, chemistry and automation to discover potent, evolutionarily-refined small molecules and their cognate targets directly from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs.
Location: United States, California, Menlo Park
Employees: 51-200
Total raised: $232.3M
Investors 4
| Date | Name | Website |
| - | LeFrak | lefrak.com |
| - | 8VC | 8vc.com |
| 17.07.2020 | The Column... | thecolumng... |
| - | Two Sigma ... | twosigmave... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 13.02.2023 | Series B | $77.3M | - |
| 26.09.2022 | Series A | $47M | - |
| 22.09.2021 | - | $61M | Nextech In... |
| 16.09.2020 | Series A | $47M | - |
Mentions in press and media 21
| Date | Title | Description |
| 09.03.2023 | Sequencing the Earth for Cures, with Hexagon Bio’s Maureen Hillenmeyer | Towards a pipeline of differentiated medicines, bolstered by genomics, data science, and synthetic biology breakthroughs Twenty years ago, Maureen was working at a lab at the University of Notre Dame, just as The Human Genome Project was b... |
| 13.02.2023 | Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules | - |
| 13.02.2023 | Hexagon Bio Lands $77.3 Million Series B | MENLO PARK, CA, Hexagon Bio, a biopharmaceutical company, has raised a $77.3 million Series B financing. >> Click here for more funding data on Hexagon Bio >> To export Hexagon Bio funding data to PDF and Excel, click here ... |
| 13.02.2023 | Hexagon Bio Raises $77.3M to Expand Mining Microbial Genomes | What You Should Know: |
| 30.11.2022 | 10 Predictions for 2023 | Innovations making data and software do more for the world1. Large Language Models and Generative AI will emerge as foundational technologies for a new generation of applications. – Villi Iltchev I predict we will see a new generation of e... |
| 26.09.2022 | Hexagon Bio Raises a $47 Million Series A to Develop Fungi-Based Medicine | 3 Mins Read California-based Hexagon Bio has closed a $47 million Series A funding round led by The Column Group, with participation from 8VC and Two Sigma Ventures. Hexagon is using first-of-its-kind proprietary genomics technology to deve... |
| 07.10.2021 | Pluton Biosciences looks to nature for cutting-edge biotech solutions, raising $6.6M seed | Many of the problems we face today in biology and agriculture have been faced before — but not by humans. Somewhere in nature there is a microscopic creature that accomplishes naturally and efficiently what chemists and bioengineers are str... |
| 27.09.2021 | Digital health news, funding roundup in the prior week; September 27 | UnitedHealthcare makes Apple Fitness available at no cost; Devoted lands $1.2 billion! More healthtech companies are going public, but are they measuring up? A number of 2021 healthtech companies are trading below their IPO price, with redu... |
| 23.09.2021 | Daily funding roundup - September 23, 2021 | NTWRK raised $50M; Bigeye landed $45M; Meru Health secured $30 Opentrons Labworks: Opentrons Labworks is a Brooklyn, N.Y.-based robotics company focused on helping life scientists automate many of their experiments and processes. Opentrons ... |
| 22.09.2021 | Hexagon Bio : Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes | Hexagon Bio, a biopharmaceutical company pioneering the discovery of medicines encoded in the global metagenome, today announced that it has raised $61 million to fuel the continued development of its platform to design and develop new ther... |
Show more